Furthermore, KDM3A targeting increased response to anti-angiogenic therapies, disclosing a role in tumor angiogenesis43 Interestingly, in vitro studies in lung and breast cancer cells demonstrated that KDM6A inhibition decreased cell survival and improved RT response, through H3K27me3 enhancement44. Here, KDM6A is linked to breast cancer.